All News

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert announced that it completed patient enrollment in its Phase 2a trial evaluating CTP-543 for alopecia areata. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert is scheduled to present at the upcoming Cowen, Oppenheimer and H.C. Wainwright healthcare conferences. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert reported financial results for the year ended December 31, 2017, and provided an update on its product pipeline and corporate activities. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert selected CTP-692 for adjunctive treatment of schizophrenia, a chronic illness with significant unmet need, as its next development candidate. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2017, on Thursd... more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--The Company initiated enrollment of the second cohort of its Phase 2a clinical trial evaluating CTP-543 for the treatment of alopecia areata. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--FDA has granted Fast Track designation for CTP-543, a novel, JAK inhibitor for the treatment of moderate-to-severe alopecia areata. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--PTAB decided not to grant the Company’s PGR petition. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Marc Becker will join Concert as Chief Financial Officer, effective January 4, 2018. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert has been selected for addition to the NBI effective prior to the market open on December 18, 2017 more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert third quarter of 2017 financial results. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert has completed enrollment of the first cohort of its Phase 2a trial evaluating CTP-543 for alopecia areata. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert will report third quarter financial results on November 9th. The Company is also scheduled to participate at several healthcare conferences. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Incyte’s IPR petition challenging Concert's CTP-543 patent was denied by PTAB. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert to present at Wells Fargo Securities 2017 Healthcare Conference on September 7, 2017. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert reported financial results for the second quarter of 2017. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2017 financial results on Tuesday, August 8, 2017,... more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--The FTC has terminated the waiting period under the HSR Act for the pending sale of CTP-656 by Concert to Vertex. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--The FDA has lifted the clinical hold on Concert’s CTP-543 Phase 2a clinical trial. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert entered into a $30 million venture debt financing agreement with Hercules Capital. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--In June, Concert will present at both the Jefferies Global Healthcare Conference and the JMP Securities Life Sciences Conference. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that Ryan Daws, Chief Financial Officer, will be leaving the company in early June 2017 t... more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert shareholders voted to approve the asset purchase agreement under which Vertex Pharmaceuticals will acquire CTP-656 for the treatment of cystic... more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received a request for additional information (“Second Request”) from the Uni... more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that its CTP... more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert reported financial results for the first quarter of 2017. more »

LEXINGTON, Mass.--(EON: Enhanced Online News)--Concert initiated a Phase 2a clinical trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata. more »